substance p has been researched along with Apoplexy in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, LH; Liu, QQ; Long, JJ; Wang, CB; Wang, YL; Xiao, P; Zhang, X; Zhang, XH | 1 |
| Cao, CC; Feng, HY; Lv, HL; Ren, LJ; Wang, YL; Zhang, X; Zhang, XH | 1 |
| Fritsch, B; Greiner, KL; Hosp, JA; Löffler, F; Martinez Arellano, L; Reis, J; Roth, F | 1 |
| Bubak, AN; Como, CN; Das, A; Doyle-Meyers, L; Feia, B; Looper, J; Mahalingam, R; Nagel, MA; Pearce, CM; Traina-Dorge, V | 1 |
| Bittner, S; Claus, I; Dziewas, R; Marian, T; Meuth, SG; Minnerup, J; Muhle, P; Ruck, T; Schröder, JB; Suntrup-Krueger, S; Warnecke, T | 1 |
| Abo, M; Fujigasaki, H; Hara, T; Hashimoto, G; Ide, T; Niimi, M; Yamada, N | 1 |
| Gao, Y; Li, J; Li, Y; Su, M | 1 |
| Almeida, T; Argueso, M; Hernández, M; Lorente, L; Martín, MM; Pérez-Cejas, A; Ramos, L; Riaño-Ruiz, M; Solé-Violán, J | 1 |
| Hibi, S; Ishii, M; Kume, H; Ouchi, Y; Teramoto, S; Yamaguchi, Y; Yamamoto, H | 1 |
| Gao, X; Ji, X; Li, L; Luo, Y; Wei, H; Zhao, J | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nishiyama, Y; Ueda, M | 1 |
| Arai, T; Fujiwara, H; Sekizawa, K; Yoshimi, N | 1 |
| Blumbergs, PC; Helps, SC; Rodgers, KM; Sims, NR; Turner, RJ; Vink, R | 1 |
| Blomstrand, C; Hrafnkelsdóttir, T; Jern, C; Jern, S; Jood, K | 1 |
| Turner, R; Vink, R | 2 |
| Barrett, NE; Emerson, M; Gibbins, JM; Hunt, SP; Jones, S; Kaiser, WJ; Lowry, PJ; Sage, T; Tucker, KL; Zimmer, A | 1 |
| Arai, T; Fujiwara, H; Kashiki, Y; Takaya, T; Toshima, S; Yasuda, Y; Yoshimii, N | 1 |
| Arai, T; Fujiwara, H; Kashiki, Y; Takaya, T; Toshima, S; Yasuda, Y; Yoshimi, N | 1 |
| Arai, T; Fujiwara, H; Kashiki, Y; Shibayama, M; Takaya, T; Toshima, S; Yasuda, Y; Yoshimi, N | 1 |
2 review(s) available for substance p and Apoplexy
| Article | Year |
|---|---|
Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke.
Topics: Animals; Brain Edema; Brain Ischemia; Encephalitis; Humans; Stroke; Substance P | 2007 |
Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke.
Topics: Animals; Brain Edema; Brain Injuries; Humans; Neurogenic Inflammation; Neurokinin-1 Receptor Antagonists; Stroke; Substance P | 2007 |
6 trial(s) available for substance p and Apoplexy
| Article | Year |
|---|---|
[Acupuncture with smoothing liver and regulating
Topics: Acupuncture Points; Acupuncture Therapy; Constipation; Gastrointestinal Agents; Humans; Lactulose; Liver; Motilin; Qi; Somatostatin; Stroke; Substance P; Treatment Outcome; Vasoactive Intestinal Peptide | 2017 |
Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.
Topics: Aged; Aspirin; Cilostazol; Cross-Over Studies; Deglutition Disorders; Double-Blind Method; Humans; Male; Phosphodiesterase Inhibitors; Saliva; Stroke; Substance P; Tetrazoles | 2008 |
Nicergoline increases serum substance P levels in patients with an ischaemic stroke.
Topics: Aged; Aged, 80 and over; Basal Ganglia; Biomarkers; Brain Ischemia; Central Nervous System Agents; Deglutition; Female; Humans; Magnetic Resonance Imaging; Male; Nicergoline; Pneumonia, Aspiration; Radioimmunoassay; Stroke; Substance P; Time Factors; Treatment Outcome; Up-Regulation | 2010 |
Serum substance P concentrations and silent aspiration in elderly patients with stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Imidazolidines; Male; Pneumonia, Aspiration; Stroke; Substance P; Treatment Outcome | 2003 |
Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Deglutition Disorders; Female; Humans; Hypertension; Imidazoles; Imidazolidines; Losartan; Male; Pneumonia, Aspiration; Stroke; Substance P | 2000 |
Angiotensin II receptor antagonists cannot prevent symptomless dysphagia in hypertensive bedridden older patients with stroke.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bed Rest; Case-Control Studies; Deglutition Disorders; Female; Humans; Hypertension; Losartan; Male; Stroke; Substance P; Treatment Outcome | 2000 |
12 other study(ies) available for substance p and Apoplexy
| Article | Year |
|---|---|
Correlation research of serum substance P, CCK-8, and 5-HT values with depression levels in stroke survivors.
Topics: Cholecystokinin; Humans; Serotonin; Sincalide; Stroke; Substance P; Survivors | 2023 |
An investigation on the changes of serum CCK-8, substance P, and 5-HT in patients with post-stroke insomnia.
Topics: Cholecystokinin; Humans; Serotonin; Sincalide; Sleep Initiation and Maintenance Disorders; Stroke; Substance P | 2023 |
Progressive secondary exo-focal dopaminergic neurodegeneration occurs in not directly connected midbrain nuclei after pure motor-cortical stroke.
Topics: Animals; Dopaminergic Neurons; Male; Mesencephalon; Motor Cortex; Nerve Degeneration; Rats; Rats, Sprague-Dawley; Stroke; Substance P; Substantia Nigra | 2020 |
Elevated serum substance P during simian varicella virus infection in rhesus macaques: implications for chronic inflammation and adverse cerebrovascular events.
Topics: Animals; Biomarkers; Gene Expression; Herpesvirus 3, Human; Immunosuppressive Agents; Inflammation; Macaca mulatta; Male; Risk; Stroke; Substance P; Tacrolimus; Varicella Zoster Virus Infection; Virus Activation; Whole-Body Irradiation | 2020 |
Increase of Substance P Concentration in Saliva after Pharyngeal Electrical Stimulation in Severely Dysphagic Stroke Patients - an Indicator of Decannulation Success?
Topics: Aged; Aged, 80 and over; Deglutition Disorders; Electric Stimulation; Female; Humans; Male; Middle Aged; Pharynx; Prospective Studies; Saliva; Stroke; Substance P; Tracheostomy | 2017 |
Relationship Between Frequency of Spontaneous Swallowing and Salivary Substance P Level in Patients with Acute Stroke.
Topics: Aged; Cough; Deglutition; Female; Humans; Male; Middle Aged; Saliva; Stroke; Substance P | 2018 |
Serum Levels of Substance P and Mortality in Patients with a Severe Acute Ischemic Stroke.
Topics: Aged; Biomarkers; Female; Glasgow Coma Scale; Humans; Infarction, Middle Cerebral Artery; Male; Middle Aged; Stroke; Substance P; Survival Rate | 2016 |
Plasma and cerebrospinal fluid substance P in post-stroke patients with depression.
Topics: Adult; Aged; Aged, 80 and over; Brain; Depression; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Stroke; Substance P | 2009 |
Increased substance P immunoreactivity and edema formation following reversible ischemic stroke.
Topics: Animals; Brain Edema; Cerebral Cortex; Inflammation Mediators; Male; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Stroke; Substance P | 2006 |
Local tissue-type plasminogen activator release in patients with ischemic stroke.
Topics: Brachial Artery; Brain Ischemia; Case-Control Studies; Forearm; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Stroke; Substance P; Tissue Plasminogen Activator | 2007 |
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation.
Topics: Animals; Bleeding Time; Blood Flow Velocity; Blood Platelets; Hemostasis; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Myocardial Infarction; Platelet Activation; Receptors, Neurokinin-1; Stroke; Substance P; Thromboembolism | 2008 |
Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, and pneumonia in elderly hypertensive patients with stroke.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Humans; Hypertension; Pneumonia; Stroke; Substance P | 2001 |